EGFR
EGFR (epidermal growth factor receptor) inhibitors are compounds that block the signaling of EGFR, a receptor that is often overexpressed in various cancers and plays a critical role in angiogenesis. EGFR inhibitors are used to prevent tumor growth and metastasis by disrupting the pathways that promote blood vessel formation in tumors. These inhibitors are widely used in cancer research and therapy. At CymitQuimica, we offer a diverse selection of high-quality EGFR inhibitors to support your research in oncology and angiogenesis.
Found 572 products of "EGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Gefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Formula:C22H24ClFN4O41·5HClColor and Shape:SolidMolecular weight:517.59HER2-IN-13
CAS:<p>HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with an</p>Formula:C26H23ClF2N8O3Color and Shape:SolidMolecular weight:568.96Oritinib
CAS:<p>Oritinib (SH-1028) is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (</p>Formula:C31H37N7O2Purity:99.62%Color and Shape:SoildMolecular weight:539.67Simotinib hydrochloride
CAS:<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Formula:C25H27Cl2FN4O4Color and Shape:SolidMolecular weight:537.41YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Color and Shape:Odour LiquidDSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Color and Shape:Odour SolidMS9427 TFA
<p>MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.</p>Formula:C50H59ClF4N8O14Color and Shape:SolidMolecular weight:1107.5EGFR-IN-140
<p>EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.</p>Formula:C27H37FN8O2Color and Shape:SolidMolecular weight:524.633Azerutamig
<p>Azerutamig is a dual-specificity antibody targeting KLRK1/ERBB2 of type (H-γ1_L-κ)_scFvkh-H-γ1(h-CH2-CH3).</p>Color and Shape:Odour LiquidMS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Formula:C48H58ClFN8O12Color and Shape:SolidMolecular weight:993.47EGFR-IN-127
<p>EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).</p>Color and Shape:Odour SolidAmivantamab (FUT8-KO)
<p>Amivantamab (FUT8-KO) is a humanized dual-specificity antibody targeting EGFR-MET, exhibiting immunotherapeutic anticancer activity. This compound inhibits ligand binding, enhances the internalization and degradation of receptor-antibody complexes, and stimulates macrophage-mediated phagocytosis and natural killer cell cytotoxicity, both of which are Fc-dependent.</p>Formula:C13H12O4Color and Shape:LiquidMolecular weight:232.23PROTAC EGFR degrader 10
CAS:<p>PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.</p>Formula:C49H65ClN10O7SColor and Shape:SolidMolecular weight:973.62PROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Formula:C58H72ClFN12O8SColor and Shape:SolidMolecular weight:1151.78Cetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Color and Shape:Odour LiquidDSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Color and Shape:Odour SolidSOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Formula:C25H29F3N4O3Color and Shape:SolidMolecular weight:490.52Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Purity:95% - 95%Color and Shape:LiquidEGFR ligand-11
CAS:<p>EGF Rligand-11, a target protein ligand for EGFR, is utilized in the synthesis of PROTAC MS154.</p>Formula:C25H29ClFN5O4Color and Shape:SolidMolecular weight:517.98Nezutatug
CAS:<p>Nezutatug, an anti-HER3 antibody, serves as a research tool in cancer studies [1].</p>Purity:98%Color and Shape:LiquidMC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:<p>MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.</p>Formula:C52H72N12O11Purity:97.70%Color and Shape:SolidMolecular weight:1041.2Laprituximab
CAS:<p>Laprituximab (J2898A) is a humanized anti-EGFR antibody used for synthesizing ADC compound Laprituximab emtansine.</p>Purity:>95%Color and Shape:LiquidEGFR-IN-138
<p>EGFR-IN-138 (compound 19) is a potent inhibitor of EGFR, with IC50 values of 37, 2.6, and 1.9 nM for the wild-type, L858R, and T790M EGFR, respectively.</p>Formula:C42H37N7O5Color and Shape:SolidMolecular weight:719.79OK2
<p>OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.</p>Formula:C42H62N14O9Purity:98%Color and Shape:SolidMolecular weight:907.03EGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Formula:C26H20ClFN4OSColor and Shape:SolidMolecular weight:490.984-Epidoxycycline
CAS:<p>4-Epidoxycycline is a hepatic metabolite of the antibiotic doxycycline and lacks antibiotic properties in mice. In both in vitro assays and in vivo mouse models, 4-Epidoxycycline regulates HER2 gene expression similarly to doxycycline and exhibits comparable efficacy in tumor tissues, achieving over 95% tumor regression rates.</p>Formula:C22H24N2O8Color and Shape:SolidMolecular weight:444.44ErbB-2-binding peptide
CAS:<p>ErbB-2-binding peptide (HER2-binding peptide), a tumor-targeting peptide, holds potential for cancer research applications [1].</p>Formula:C43H60N8O11Color and Shape:SolidMolecular weight:864.98Etevritamab
CAS:<p>Etevritamab is a monoclonal antibody that targets CD3E/EGFR.</p>Color and Shape:LiquidAMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Color and Shape:Odour LiquidVarlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Formula:C36H35ClN6O8S3Purity:98%Color and Shape:SolidMolecular weight:811.34EGFR-IN-128
<p>EGFR-IN-128 (compound 28) is a potent and selective molecule targeting wild-type EGFREx20Ins, demonstrating therapeutic efficacy across various human xenograft models and capable of penetrating the blood-brain barrier in preclinical species.</p>Formula:C27H20N4OColor and Shape:SolidMolecular weight:416.47EGFRvIII peptide (PEPvIII)
CAS:<p>PEPvIII, a peptide sequence from EGFRvIII, was designed to represent a target of glioma and is presented by MHC I/II complexes.</p>Formula:C70H111N19O24SPurity:98%Color and Shape:SolidMolecular weight:1634.81DSPE-PEG5000-GE11
<p>DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.</p>Color and Shape:Odour SolidCoprelotamab
CAS:<p>Coprelotamab (GB-221) is an IgG-κ monoclonal antibody that targets EGFR2, frequently produced in CHO DG44 (Chinese Hamster Ovary) cells [1].</p>Purity:98%Color and Shape:LiquidPROTAC EGFR degrader 8
CAS:<p>PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.</p>Formula:C40H46ClN11O5Purity:98%Color and Shape:SolidMolecular weight:796.32EGFR-IN-84
<p>EGFR-IN-84 (Compound 6g), an EGFR inhibitor with an IC50 of 24 nM, impedes the growth of A549 cells with an IC50 value of 1.537 μM and is utilized for lung</p>Formula:C25H20N6O3S2Purity:98%Color and Shape:SolidMolecular weight:516.59EGFR-IN-81
<p>EGFR-IN-81 (Compound 10i), an EGFR inhibitor, demonstrates potent activity by inhibiting EGFR WT and the L858R/T790M mutation at IC50 values of 4.38 nM and 5.69</p>Formula:C28H24F3N5O4Purity:98%Color and Shape:SolidMolecular weight:551.52MTX-241F
<p>MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.</p>Formula:C20H14ClFN6Purity:98%Color and Shape:SolidMolecular weight:392.82Dacomitinib metabolite M2
CAS:<p>Dacomitinib metabolite M2 is also known as Dacomitinib cysteine conjugate. Dacomitinib inhibits both the wild-type (WT) EGFR and EGFR T790M.</p>Formula:C27H32ClFN6O4SColor and Shape:SolidMolecular weight:591.1Anti-ERBB3/HER3 (29Z6)
<p>Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.</p>Color and Shape:Odour LiquidZM 449829
CAS:<p>ZM 449829: Selective JAK3 inhibitor, binds to ATP site. pIC50: 6.8 for JAK3, others < 5.0.</p>Formula:C13H10OPurity:98%Color and Shape:SolidMolecular weight:182.222FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Color and Shape:LiquidEGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Formula:C17H15N7O5SColor and Shape:SolidMolecular weight:429.41EGFR T790M/L858R-IN-9
<p>EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.</p>Formula:C26H27N7O3SColor and Shape:SolidMolecular weight:517.603EGFR-IN-15
CAS:<p>EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.</p>Formula:C24H25BrN6O2Color and Shape:SolidMolecular weight:509.408Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Formula:C41H74N2O20Color and Shape:SolidMolecular weight:915.028Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Color and Shape:Odour SolidKRAS G12D inhibitor 25
CAS:<p>KRAS G12D inhibitor 25 (Compound 148) acts as an inhibitor for KRAS G12C and HSP90α, displaying IC50 values of <0.1 μM and 0.1-1 μM respectively. Additionally, it suppresses the proliferation of MIA PaCa-2 and NCI-H358 cell lines, with EC50 values of <0.1 μM and 0.1-1 μM correspondingly. This compound also promotes the degradation of ERBB2, exhibiting a DC50 of 0.1-1 μM.</p>Formula:C56H62ClN11O6Color and Shape:SolidMolecular weight:1020.62Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Color and Shape:Odour SolidFicerafusp alfa
<p>Ficerafusp alfa is a chimeric antibody of the IgG1κ type that targets EGFR, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>Color and Shape:Odour LiquidEGFR/BRAFV600E-IN-2
<p>E07 Aptamer, targeting the human epidermal growth factor receptor (hEGFR), competes with epidermal growth factor (EGF) for binding to a unique epitope on EGFR.</p>Formula:C25H18N4O2Purity:98%Color and Shape:SolidMolecular weight:406.44EGFR-IN-148
<p>EGFR-IN-148 (compound 8c) is a potent EGFR inhibitor with an IC50 of 0.161 μM. It induces G1/S phase arrest and significantly enhances apoptosis in HepG2 cells.</p>Formula:C17H16N4O4SColor and Shape:SolidMolecular weight:372.398EGFR-IN-79
<p>EGFR-IN-79 (compound 21), an EGFR inhibitor, exhibits antitumor activity through ROS-independent apoptosis and EGFR/AKT/mTOR-mediated autophagy.</p>Formula:C23H16ClN3O3Purity:98%Color and Shape:SolidMolecular weight:417.84EGFR-IN-90
<p>EGFR-IN-90 (compound 34), an orally active EGFR inhibitor, demonstrates potent activity against EGFRL858R/T790M/C797S with an IC50 of 5.1 nM and effectively</p>Purity:98%Color and Shape:Odour SolidBI-4732
CAS:<p>DL-Homocystine is a mutagen secreted by F. nucleatum.</p>Formula:C32H36N10O2Purity:98.88%Color and Shape:SolidMolecular weight:592.69CN009543V
CAS:<p>CN009543V is an enhancer of tyrosine phosphorylation of EGFR via downstream signaling pathways.</p>Formula:C12H12N4O6SColor and Shape:SolidMolecular weight:340.31EGFR-IN-93
<p>EGFR-IN-93 (compound 18) is an allosteric inhibitor of the T790M/L858R double mutant EGFR. It is applicable for research in non-small cell lung cancer (NSCLC).</p>Formula:C22H18FN3O3Molecular weight:391.13322Modotuximab
CAS:<p>Modotuximab (DS 1024) is a humanized antibody targeting EGFR with antitumor activity that accelerates the internalization and degradation of EGFR.</p>Purity:95.5% (SDS-PAGE); 99.3% (SEC-HPLC) - 95.5% (SDS-PAGE); 99.3% (SEC-HPLC)Color and Shape:LiquidAnticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Color and Shape:Odour SolidMatuzumab
CAS:<p>Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR that can be used to study non-small cell lung cancer.</p>Purity:95%Color and Shape:LiquidMolecular weight:145.9 kDaEGFR-IN-95
<p>EGFR-IN-95 is a derivative of 2,4-diaminonicotinamide. It effectively inhibits the activity of EGFRdel19/T790M/C797S and L858R/T790M/C797S.</p>Formula:C23H28F2N8O3SMolecular weight:534.19731Necitumumab
CAS:<p>Necitumumab (IMC-11F8) is a human monoclonal antibody against EGFR, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer.</p>Purity:97.9% (SDS-PAGE); 99.1% (SEC-HPLC) - 97.9% (SDS-PAGE); 99.1% (SEC-HPLC)Color and Shape:LiquidMolecular weight:145.5 kDaCetuximab MMAE
<p>Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.</p>Color and Shape:LiquidMolecular weight:150 kDaEGFR-IN-136
<p>EGFR-IN-136 (compound 21v) is a potent inhibitor of EGFR, demonstrating IC50 values of 20.2 nM, 1.2 nM, 2.3 nM, and 12.5 nM for EGFRWT, EGFRLR/TM, EGFR19D/TM/CS, and EGFRLR/TM/CS, respectively. It exhibits antiproliferative and antitumor activities and holds potential for research in non-small cell lung cancer (NSCLC).</p>Formula:C30H36N7O4PColor and Shape:SolidMolecular weight:589.625HER2-IN-20
<p>HER2-IN-20 (compound 32) is a potent and selective inhibitor of HER2WT and HER2YVMA, with IC50 values of 49 and 42 nM, respectively. It holds potential for research in non-small cell lung cancer (NSCLC).</p>Formula:C30H27ClFN7O2Molecular weight:571.18988PROTAC EGFR degrader 11
CAS:<p>PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.</p>Formula:C49H64ClFN10O7SColor and Shape:SolidMolecular weight:991.61BLU-945
CAS:<p>BLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).Cost-effective and quality-assured.</p>Formula:C28H37FN6O3SPurity:99.11% - 99.16%Color and Shape:SolidMolecular weight:556.7SJF 1528
CAS:<p>Potent EGFR & HER2 degrader; DC50 of 39.2 nM in OVCAR8, 736 nM in HeLa; has lapatinib, VHL ligand; inhibits HER2+ breast cancer (IC50=102 nM for SKBr3).</p>Formula:C55H57ClFN7O8SColor and Shape:SolidMolecular weight:1030.61EGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Color and Shape:Odour SolidTephrosin
CAS:<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Formula:C23H22O7Purity:98%Color and Shape:SolidMolecular weight:410.42Varlitinib
CAS:<p>Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.</p>Formula:C22H19ClN6O2SPurity:99.7%Color and Shape:SolidMolecular weight:466.94EGFR-IN-116
<p>EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.</p>Formula:C26H22N6O2SMolecular weight:482.1525PRMT5/EGFR-IN-1
<p>PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual inhibitor targeting PRMT5 and EGFR, with IC50 values of 15.47 μM and 19.31 μM, respectively. It demonstrates antiproliferative activity against the A549, MCF7, HeLa, and MDA-MB-231 cell lines. This compound also exhibits favorable pharmacokinetic (PK) and pharmacodynamic (PD) properties in vivo and significantly inhibits the growth of MCF7 orthotopic xenograft tumors.</p>Formula:C27H22F6N2O2Molecular weight:520.15855EGFR kinase inhibitor 2
<p>EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting the mutations EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S. This compound shows potential in addressing acquired resistance in the treatment of non-small cell lung cancer.</p>Formula:C39H40N6O5Molecular weight:672.30602HER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Formula:C42H77N9O11Purity:98%Color and Shape:SolidMolecular weight:884.11EGFR-IN-110
<p>EGFR-IN-110 (Compound 6) is a covalent inhibitor of EGFR, demonstrating pIC50 values of 9.2 for the EGFR enzyme and 8.7 for EGFR cells. It exhibits strong efficacy in targeting EGFR and maintains good kinase selectivity.</p>Formula:C22H16ClFN4O2Molecular weight:422.09458AG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Formula:C16H15Cl2N3O2Color and Shape:SolidMolecular weight:352.21EGFR WT/T790M/L858R-IN-1
<p>EGFRWT/T790M/L858R-IN-1 (compound 10d) is a potent inhibitor of EGFR, demonstrating IC50 values of 0.097, 0.280, and 0.051 μM for EGFRWT, EGFRT790M, and EGFRL858R, respectively. This compound can be utilized in cancer research.</p>Formula:C26H25Cl3N2O3Molecular weight:518.09308MS39N
CAS:<p>MS39N (compound 27) serves as the negative control for MS39, capable of binding to EGFR without causing its degradation.</p>Formula:C55H71ClFN9O7SMolecular weight:1056.73BMS-599626
CAS:<p>BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.</p>Formula:C27H27FN8O3Purity:98.73%Color and Shape:SolidMolecular weight:530.55Pertuzumab
CAS:<p>Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2</p>Purity:98.00%Color and Shape:LiquidMolecular weight:148 kDaSJF 1521
CAS:<p>SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.</p>Formula:C57H61ClFN7O9SPurity:99.20%Color and Shape:SolidMolecular weight:1074.65JBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Formula:C33H30F4N4O5SColor and Shape:SolidMolecular weight:670.67EGFR-IN-76
CAS:<p>EGFR-IN-76 is a potent EGFR inhibitor.</p>Formula:C30H30ClFN6O2Purity:97.02% - 97.72%Color and Shape:SolidMolecular weight:561.05Istiratumab
CAS:<p>Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.</p>Color and Shape:LiquidEGFR-IN-129
<p>EGFR-IN-129 (Compound 10b) is an effective, selective EGFR inhibitor with an IC50 of 51.2 nM and demonstrates broad-spectrum antiproliferative activity against the NCI tumor panel.</p>Formula:C21H18N4O3SColor and Shape:SolidMolecular weight:406.46EP26
<p>EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research.</p>Formula:C42H42ClFN4O5Molecular weight:736.28278EGFR/HER2-IN-15
<p>EGFR/HER2-IN-15 is a dihydropyrimidine and an effective inhibitor of EGFR/HER2. It significantly suppresses EGFRwt activity with an IC50 of 37.21 nM and exhibits anticancer properties.</p>Formula:C28H29N3O6Molecular weight:503.20564CZY43
<p>CZY43 is an HER3 degrader that effectively induces degradation of HER3 in breast cancer SKBR3 cells in a dose- and time-dependent manner. It efficiently inhibits HER3-dependent signaling and cancer cell growth, outperforming Bosutinib.</p>Formula:C42H53Cl2N5O3Color and Shape:SolidMolecular weight:746.808EGFR T790M/L858R-IN-6
CAS:<p>EGFR T790M/L858R-IN-6 (compound 53), classified as a pyrimidine compound, serves as an effective inhibitor of EGFR T790M/L858R, demonstrating 90.88% inhibition of enzyme activity at a concentration of 0.05 μM [1].</p>Formula:C27H27N7O2Color and Shape:SolidMolecular weight:481.55Pimurutamab
CAS:<p>Pimurutamab, a humanized IgG1-κ antibody, selectively targets the epidermal growth factor receptor (EGFR) and is primarily produced by CHO-K1 cells [1].</p>Purity:98%Color and Shape:LiquidCanertinib
CAS:Formula:C24H25ClFN5O3Purity:>98.0%(HPLC)(qNMR)Color and Shape:White to Light yellow powder to crystalMolecular weight:485.94Vandetanib
CAS:Formula:C22H24BrFN4O2Purity:>98.0%(T)(HPLC)Color and Shape:White to Light yellow powder to crystalMolecular weight:475.36Tyrphostin AG 879
CAS:Formula:C18H24N2OSPurity:>98.0%(HPLC)Color and Shape:Light yellow to Yellow to Orange powder to crystalMolecular weight:316.46AV-412 free base
CAS:<p>AV-412 free base is an EGFR inhibitor (IC50s: 0.75, 0.79, 0.5, 2.3, 19 nM for EGFR, EGFR(T790M), EGFR(L858R), EGFR(L858R/T790M) and ErbB2).</p>Formula:C27H28ClFN6OColor and Shape:SolidMolecular weight:507Tyrphostin RG 14620
CAS:Formula:C14H8Cl2N2Purity:>98.0%(HPLC)Color and Shape:White to Light yellow powder to crystalMolecular weight:275.13Erlotinib-d6
CAS:<p>Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR. Erlotinib D6 is a deuterium labeled Erlotinib .</p>Formula:C22H23N3O4Purity:98%Color and Shape:SolidMolecular weight:399.47Osimertinib dimesylate
CAS:<p>Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M).</p>Formula:C30H41N7O8S2Purity:98%Color and Shape:SolidMolecular weight:691.82CL-387785
CAS:Formula:C18H13BrN4OPurity:>98.0%(GC)Color and Shape:White to Light yellow powder to crystalMolecular weight:381.23Mavelertinib
CAS:<p>Mavelertinib (PF-06747775) is an EGFR tyrosine kinase (EGFR TKI) inhibitor that inhibits T790M/L858R and can be used to study tumours.</p>Formula:C18H22FN9O2Purity:99.89%Color and Shape:SolidMolecular weight:415.42
